Auranofin Suppresses Plasminogen Activator Inhibitor-2 Expression through Annexin A5 Induction in Human Prostate Cancer Cells
- Authors
- Shin, Dong-Won; Kwon, Yeo-Jung; Ye, Dong-Jin; Baek, Hyoung-Seok; Lee, Joo-Eun; Chun, Young-Jin
- Issue Date
- Mar-2017
- Publisher
- KOREAN SOC APPLIED PHARMACOLOGY
- Keywords
- Annexin A5; Apoptosis; Auranofin; Plasminogen activator inhibitor-2
- Citation
- BIOMOLECULES & THERAPEUTICS, v.25, no.2, pp 177 - 185
- Pages
- 9
- Journal Title
- BIOMOLECULES & THERAPEUTICS
- Volume
- 25
- Number
- 2
- Start Page
- 177
- End Page
- 185
- URI
- https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/4699
- DOI
- 10.4062/biomolther.2016.223
- ISSN
- 1976-9148
2005-4483
- Abstract
- Auranofin has been developed as antirheumatic drugs, which is currently under clinical development for the treatment of chronic lymphocytic leukemia. Previous report showed that auranofin induced apoptosis by enhancement of annexin A5 expression in PC-3 cells. To understand the role of annexin A5 in auranofin-mediated apoptosis, we performed microarray data analysis to study annexin A5-controlled gene expression in annexin A5 knockdown PC-3 cells. Of differentially expressed genes, plasminogen activator inhibitor (PAI)-2 was increased by annexin A5 siRNA confirmed by qRT-PCR and western blot. Treatment with auranofin decreased PAI-2 and increased annexin A5 expression as well as promoting apoptosis. Furthermore, auranofin-induced apoptosis was recovered by annexin A5 siRNA but it was promoted by PAI-2 siRNA. Interestingly, knockdown of annexin A5 rescued PAI-2 expression suppressed by auranofin. Taken together, our study suggests that induction of annexin A5 by auranofin may enhance apoptosis through suppression of PAI-2 expression in PC-3 cells.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Pharmacy > School of Pharmacy > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.